JEIL PHARMACEUTICAL CO.,LTD Logo

JEIL PHARMACEUTICAL CO.,LTD

Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.

271980 | KO

Overview

Corporate Details

ISIN(s):
KR7271980005
LEI:
Country:
South Korea
Address:
서울특별시 서초구 사평대로 343 제일약품 사옥, 서초구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Founded in 1959, Jeil Pharmaceutical Co., Ltd. develops, manufactures, and distributes pharmaceutical products to promote human health. The company's core activities include the production of active pharmaceutical ingredients (APIs), intermediates, and finished medicines, with a notable focus on injection-based treatments. Operating from GMP-certified facilities, Jeil Pharmaceutical's portfolio includes various therapeutic agents, such as antibiotics. The company is expanding its reach from its domestic market to a global scale, supplying its products to other nations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-06-04 00:00
Governance Information
[기재정정]기업지배구조보고서공시
Korean 959.3 KB
2025-05-29 00:00
Governance Information
기업지배구조보고서공시
Korean 952.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.5 MB
2025-03-25 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.9 KB
2025-03-25 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.7 KB
2025-03-25 00:00
Board/Management Information
대표이사(대표집행임원)변경(안내공시)
Korean 5.5 KB
2025-03-17 00:00
Audit Report / Information
감사보고서제출
Korean 20.8 KB
2025-03-17 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 463.9 KB
2025-03-10 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 946.6 KB
2025-03-05 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 15.5 KB
2025-02-24 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 13.8 KB
2024-12-05 00:00
Share Issue/Capital Change
[기재정정]유상증자결정(종속회사의주요경영사항)
Korean 25.8 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 1.3 MB
2024-11-08 00:00
Share Issue/Capital Change
[기재정정]유상증자결정(종속회사의주요경영사항)
Korean 23.5 KB

Automate Your Workflow. Get a real-time feed of all JEIL PHARMACEUTICAL CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JEIL PHARMACEUTICAL CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JEIL PHARMACEUTICAL CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.